Log in

NASDAQ:NBSENeuBase Therapeutics Stock Price, Forecast & News

$7.72
+0.28 (+3.76 %)
(As of 08/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$7.44
Now: $7.72
$7.81
50-Day Range
$7.25
MA: $8.72
$11.51
52-Week Range
$4.15
Now: $7.72
$11.78
Volume91,619 shs
Average Volume253,109 shs
Market Capitalization$178.49 million
P/E RatioN/A
Dividend YieldN/A
Beta0.38
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary peptide-nucleic acid antisense oligonucleotide (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders. Its lead programs include NT0100, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the HD messenger ribonucleic acid (mRNA); and NT0200, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the myotonic dystrophy type 1 disease mRNA. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.86 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NBSE
CUSIPN/A
CIKN/A
Phone646-450-1790

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.59 per share

Profitability

Net Income$-26,960,000.00

Miscellaneous

Employees12
Market Cap$178.49 million
Next Earnings Date8/12/2020 (Estimated)
OptionableNot Optionable
$7.72
+0.28 (+3.76 %)
(As of 08/3/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NBSE News and Ratings via Email

Sign-up to receive the latest news and ratings for NBSE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











NeuBase Therapeutics (NASDAQ:NBSE) Frequently Asked Questions

How has NeuBase Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

NeuBase Therapeutics' stock was trading at $7.02 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NBSE shares have increased by 10.0% and is now trading at $7.72.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of NeuBase Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeuBase Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for NeuBase Therapeutics
.

When is NeuBase Therapeutics' next earnings date?

NeuBase Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020.
View our earnings forecast for NeuBase Therapeutics
.

How were NeuBase Therapeutics' earnings last quarter?

NeuBase Therapeutics (NASDAQ:NBSE) released its quarterly earnings results on Thursday, May, 14th. The company reported ($0.26) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.22) by $0.04.
View NeuBase Therapeutics' earnings history
.

What price target have analysts set for NBSE?

6 equities research analysts have issued 1 year target prices for NeuBase Therapeutics' stock. Their forecasts range from $13.00 to $18.00. On average, they anticipate NeuBase Therapeutics' share price to reach $15.67 in the next twelve months. This suggests a possible upside of 102.9% from the stock's current price.
View analysts' price targets for NeuBase Therapeutics
.

Has NeuBase Therapeutics been receiving favorable news coverage?

Media stories about NBSE stock have been trending somewhat positive recently, according to InfoTrie. The research group rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. NeuBase Therapeutics earned a news impact score of 1.8 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days.
View the latest news about NeuBase Therapeutics
.

Who are some of NeuBase Therapeutics' key competitors?

What other stocks do shareholders of NeuBase Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeuBase Therapeutics investors own include Suncor Energy (SU), AT&T (T), AbbVie (ABBV), Walt Disney (DIS), Enbridge (ENB), Enterprise Products Partners (EPD), Energy Transfer LP Unit (ET), Roku (ROKU), Adobe (ADBE) and Alibaba Group (BABA).

Who are NeuBase Therapeutics' key executives?

NeuBase Therapeutics' management team includes the following people:
  • Dr. Dietrich A. Stephan Ph.D., Founder, Pres, CEO & Chairman (Age 50, Pay $329.78k)
  • Mr. Samuel Backenroth, CFO, Treasurer & Sec. (Age 36, Pay $337.16k)
  • Dr. Danith H. Ly, Chief Scientific Officer
  • Dr. Robert Friedlander M.D., Consulting Chief Medical Officer
  • Dr. Robert Zamboni Ph.D., Chief of Preclinical Devel.

What is NeuBase Therapeutics' stock symbol?

NeuBase Therapeutics trades on the NASDAQ under the ticker symbol "NBSE."

Who are NeuBase Therapeutics' major shareholders?

NeuBase Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include UBS Group AG (0.02%), Strs Ohio (0.02%) and Heritage Wealth Advisors (0.00%). Company insiders that own NeuBase Therapeutics stock include Dietrich A Stephan, Eric I Richman and Samuel Backenroth.
View institutional ownership trends for NeuBase Therapeutics
.

Which institutional investors are selling NeuBase Therapeutics stock?

NBSE stock was sold by a variety of institutional investors in the last quarter, including Heritage Wealth Advisors.
View insider buying and selling activity for NeuBase Therapeutics
.

Which institutional investors are buying NeuBase Therapeutics stock?

NBSE stock was purchased by a variety of institutional investors in the last quarter, including UBS Group AG, and Strs Ohio. Company insiders that have bought NeuBase Therapeutics stock in the last two years include Dietrich A Stephan, Eric I Richman, and Samuel Backenroth.
View insider buying and selling activity for NeuBase Therapeutics
.

How do I buy shares of NeuBase Therapeutics?

Shares of NBSE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is NeuBase Therapeutics' stock price today?

One share of NBSE stock can currently be purchased for approximately $7.72.

How big of a company is NeuBase Therapeutics?

NeuBase Therapeutics has a market capitalization of $178.49 million. NeuBase Therapeutics employs 12 workers across the globe.

What is NeuBase Therapeutics' official website?

The official website for NeuBase Therapeutics is www.neubasetherapeutics.com.

How can I contact NeuBase Therapeutics?

NeuBase Therapeutics' mailing address is 700 TECHNOLOGY DRIVE, PITTSBURGH PA, 15219. The company can be reached via phone at 646-450-1790 or via email at [email protected]

This page was last updated on 8/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.